Axcan to acquire Mpex, gaining Phase III candidate aerosol antibiotic for CF patients
This article was originally published in Scrip
Executive Summary
The specialty pharma company Axcan has entered into an agreement to buy all of the outstanding shares of privately held Mpex Pharmaceuticals and its lead candidate Aeroquin, a proprietary aerosol formulation of levofloxacin, which is in Phase III trials for the treatment of pulmonary infections in patients with cystic fibrosis.